West Pharmaceutical Services, Inc.

• WST Stock Price 24h change: -4.85%. From 279.41 USD to 265.86 USD. The decline was largely attributed to profit-taking and news of EULAV Asset Management reducing its stake, despite a recent earnings beat.
• From a technical perspective, the stock is showing "short-term weakness within a neutral-bullish long-term frame": WST’s 50-day moving average (~$272) remains above the 200-day moving average (~$255), but the RSI at 52.8 and the recent drop below the 50-day SMA suggest a consolidation phase. Key support is seen at $260, while resistance holds at $307.
• West Pharmaceutical Services recently reported Q3 results with revenue of $804.6 million and adjusted EPS of $1.96, both exceeding Wall Street analyst expectations of $788 million and $1.67 respectively.
• AbbVie's recent acquisition of a manufacturing facility from West Pharmaceutical has drawn investor attention to WST's strategic asset management and its role in the GLP-1 drug delivery supply chain.
• Analysts from Zacks and KeyCorp maintain a "Buy" or "Overweight" rating, citing a 26%-30% potential upside with a mean price target around $345, supported by growth in high-value product components.
• AbbVie and Genmab announced Phase 3 trial results for Epcoritamab on Jan 16, showing improved progression-free survival in lymphoma patients, which signals continued demand for advanced injectable delivery systems.
• The healthcare IT and life sciences sector is seeing a push for pricing transparency, with the HL7 FHIR standard being integrated into medical cost tools to empower patient decision-making by early 2026.

• WST Stock Price 24h change: -4.85%. From 279.41 USD to 265.86 USD. The sharp decline on January 16 was driven by news of institutional sell-offs, specifically EULAV Asset Management reducing its position, alongside broader sector volatility.
• From a technical perspective, WST shows a "bullish long-term trend under short-term pressure": the 50-day SMA ($273.01) recently crossed above the 200-day SMA ($259.32), a bullish "golden cross," but the stock currently faces strong immediate resistance at $280 and is testing support near $264 after the recent drop. RSI is neutral (47.50), suggesting the market is digesting gains rather than being oversold.
• West Pharmaceutical Services announced a definitive agreement to sell its SmartDose 3.5mL On-Body Delivery System manufacturing rights to AbbVie for $112.5 million, a strategic move to refocus its portfolio on larger dose devices.
• The company declared a quarterly dividend of $0.22 per share, payable on February 4, 2026, to shareholders of record as of January 28, representing an annualized yield of 0.3%.
• WST management presented at the 44th Annual J.P. Morgan Healthcare Conference on January 14, highlighting its 2025 EPS guidance of $7.06–$7.11 and the upcoming commercial launch of the Synchrony™ Prefillable Syringe System.
• The 44th Annual J.P. Morgan Healthcare Conference (Jan 12-15) dominated sector activity, with major announcements including Anthropic launching "Claude for Healthcare" and Eli Lilly’s $1.2 billion acquisition of Ventyx Biosciences.
• The Healthcare Select Sector SPDR (XLV) reached fresh all-time highs in early January, driven by a "Great Rebalancing" as investors rotated from overextended tech valuations into healthcare growth and value plays.